http://rdf.ncbi.nlm.nih.gov/pubchem/patent/IE-960761-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a39aaf1151602e8695bd3d1879b45561 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ef984517ad4fa88458ab2a9b88ab9961 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate | 1996-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1f44987cadf4e66ecc10c39ef7af1e1 |
| publicationDate | 1998-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | IE-960761-A1 |
| titleOfInvention | Combinations for use in increasing the potency of a¹substrate for multidrug resistance related protein |
| abstract | A combination of an agent which is a substrate for multidrug resistance related protein (MRP) and an inhibitor of MRP which is a non-steroidal anti-inflammatory drug (NSAID) or a structural analogue thereof for simultaneous, sequential or separate use for increasing the potency of the substrate. The substrates include anti-cancer drugs and transition metal complexes. The combinations can be used to overcome the resistance to MRP substrates exhibited in many conditions, such as resistance to chemotherapy where patients have developed resistance, especially as a result of MRP over-expression to their chemotherapy. |
| priorityDate | 1996-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 64.